Keytruda vs Calquence
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Keytruda | US Calquence | |
|---|---|---|
| Generic name | pembrolizumab | acalabrutinib |
| Drug class | PD-1 Inhibitor (Immunotherapy) | BTK Inhibitor |
| Treats | Multiple cancers | Chronic lymphocytic leukemia and mantle cell lymphoma |
| Category | Oncology | Oncology |
| Manufacturer | Merck | AstraZeneca |
| Year approved | 2014 | 2017 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $260M | — |
| Common side effects | Immune-related side effects, Fatigue, Rash, Diarrhea | Headache, Diarrhea, Bruising and bleeding, Infections |
Calquence
Frequently asked questions
Is Keytruda or Calquence better?
Neither is universally "better." Keytruda (pembrolizumab) and Calquence (acalabrutinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Keytruda and Calquence?
Keytruda is a PD-1 Inhibitor (Immunotherapy) made by Merck, while Calquence is a BTK Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Keytruda has the larger estimated TV advertising budget of the two.